Resistance to inhibitors of the human immunodeficiency virus type 1 integration

AUTOR(ES)

Hazuda, Daria J

FONTE

Brazilian Journal of Infectious Diseases

DATA DE PUBLICAÇÃO

2010-10

RESUMO

This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection

Documentos Relacionados

• Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors
• Monitoring Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors by Pyrosequencing
• Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors
• Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
• Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.